- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 21.04. | Gilead loosens ties to Arcus after TIGIT dream finally ends in phase 3 failure | ||
| 20.04. | AACR: Endeavoring to go global, Zai Lab offers reality check on China's biotech ascent | ||
| 20.04. | Biogen inks $850M biobucks deal with TJ Biopharma for China rights to late-stage immune antibody | ||
| 20.04. | Lilly picks up another in vivo CAR-T company with Kelonia buyout worth up to $7B | ||
| 20.04. | Novo readies SCD drug from $1.1B Forma buyout for approval push after phase 3 win | ||
| 20.04. | AstraZeneca's faith in IL-33 inhibitor continues to pay off with latest phase 3 COPD win | ||
| 20.04. | Odyssey charts fresh voyage to public markets after abandoning IPO plans last year | ||
| 20.04. | Agenus focuses on survival data as 0% response rate triggers primary miss | ||
| 20.04. | Trump orders FDA to fast-track reviews of psychedelic drugs after lobbying by podcaster | ||
| 17.04. | Merck unveils PD-1xVEGF bispecific data in NSCLC, remains tight-lipped on phase 3 plans | ||
| 17.04. | UCB pays $650M+ for Neurona, marking 'strategic expansion' into regenerative medicine | ||
| 17.04. | OpenAI launches biotech-specific AI model dubbed GPT-Rosalind | ||
| 17.04. | A new benchmark for biotech IPOs? Kailera raises $625M to fund obesity pipeline | ||
| 16.04. | Johnson & Johnson hands back failed eye disease gene therapy to MeiraGTx | ||
| 16.04. | Pfizer-backed Storm blows into $56M series C, launches phase 2 sarcoma trial | ||
| 16.04. | Aligos sells China rights to HPV drug to hepatology player Amoytop in $445M deal | ||
| 16.04. | Early-stage funding slumps toward post-pandemic low, piling more pressure on biotech startups | ||
| 15.04. | Spain sets up Boston-focused VC fund with goal of raising $200M for biotechs | ||
| 15.04. | Was Big Pharma's 'unusually aggressive' M&A spree to blame for March IPO drought? | ||
| 15.04. | Terremoto takes $108M series C to fuel clinical trials of AKT1 inhibitors | ||
| 14.04. | Cell therapy biotech Obsidian leverages Galera Therapeutics reverse merger to go public | ||
| 14.04. | Astellas to close stem cell unit's Seattle site, with layoffs incoming | ||
| 14.04. | Takeda terminates mRNA research pact with Japanese drug discovery specialist | ||
| 14.04. | Australia's Kazia pays research institute $1.4M for epigenetic platform, preclinical drug | ||
| 13.04. | FDA urges clinical trial sponsors to report the results of their studies |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.